Jeremy Er

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison, Tamia Nguyen, Marzia Rahman et al. · Blood · 2023 · 97 citations

Medicine, Hematology, Oncology +12

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study

Carmelo Carlo‐Stella, Rita Mazza, Salomon Manier et al. · Blood · 2022 · 90 citations

Medicine, Oncology, Pharmacotherapy +17

CAR+ T-Cell Lymphoma after Cilta-cel Therapy for Relapsed or Refractory Myeloma

Simon J. Harrison, Cyrille Touzeau, Nicolas Kint et al. · New England Journal of Medicine · 2025 · 51 citations

Life Sciences, Immunology, Oncology +17

Profiling the spatial architecture of multiple myeloma in human bone marrow trephine biopsy specimens with spatial transcriptomics

Raymond K. H. Yip, Jeremy Er, Quoc Hoang Nguyen et al. · Blood · 2025 · 13 citations · Full text

Medicine, Hematology, Pathology +17

Comparative efficacy of ciltacabtagene autoleucel versus idecabtagene vicleucel in the treatment of patients with relapsed or refractory multiple myeloma previously treated with 2–4 prior lines of therapy: a matching-adjusted indirect comparison

Noffar Bar, Joris Diels, Suzy Van Sanden et al. · Current Medical Research and Opinion · 2024 · 11 citations

Medicine, Internal Medicine, Oncology +16